- Record: found
- Abstract: not found
- Article: not found
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate‐to‐severe atopic dermatitis: results from the JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN phase 3 trial
Read this article at
ScienceOpen
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.